Skip to Content
Søk Menu

Nivolumab monotherapy is an effective treatment option for recurrent malignant mesothelioma

The Phase 3 study CONFIRM presented at WCLC 2020 show that nivolumab monotherapy is an effective treatment option for recurrent malignant mesothelioma.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

Pembrolizumab plus chemotherapy provided durable clinical benefit in patients with metastatic squamous NSCLC

/ Martin Reck
NSCLCWCLC20 Play the Video 8:48

Pembrolizumab with chemo-radiation therapy showed promising antitumor activity in unresectable, locally advanced, stage III NSCLC

/ Martin Reck
NSCLCWCLC20 Play the Video 7:17

Opløftende data for patienter med recidiverende malign mesotheliom

/ Jens Benn Sørensen
WCLC20 Play the Video 10:55

WCLC2020: Pembrolizumab significantly improved 5-year survival in patients with previously treated advanced NSCLC

/ Roy S. Herbst
NSCLCWCLC20 Play the Video 2:25

WCLC2020: COVID-19 outcomes in patients with thoracic malignancies

/ Umit Tapan
COVID-19WCLC20 Play the Video 16:35

12 months data from KEYNOTE-799 confirm promising response rates with pembrolizumab in combination with chemo-radiation therapy for locally advanced NSCLC

/ BestPractice Nordic
NSCLCWCLC20

Promising results with neoadjuvant atezolizumab for stage IB-IIIB NSCLC

/ BestPractice Nordic
NSCLCWCLC20

WCLC2020: Pre-operative treatment with atezolizumab in untreated stage IB-IIIB resectable NSCLC

/ Jay M. Lee
NSCLCWCLC20 Play the Video 10:38

KEYNOTE-598 confirms current standard of care in metastatic 1L NSCLC patients with PD-L1 TPS ≥50%

/ BestPractice Nordic
NSCLCWCLC20
Back to top